Is Infinium Pharma overvalued or undervalued?

As of 18 November 2025, the valuation grade for Infinium Pharma has moved from attractive to fair, indicating a shift in its perceived market value. The company is currently fairly valued, with a PE ratio of 45.72, an EV to EBITDA ratio of 24.71, and a ROE of 7.68%. In comparison to its peers, Sun Pharma has a PE ratio of 36.56 and is considered expensive, while Cipla, which is rated attractive, has a significantly lower PE ratio of 22.49.
Despite the fair valuation, Infinium Pharma's recent stock performance has been underwhelming, with a year-to-date return of -17.14%, contrasting sharply with the Sensex's gain of 9.58% over the same period. This underperformance, coupled with high valuation ratios, suggests that while the company is not overvalued, it may not present an attractive investment opportunity at this time.